Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 14
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT01361711 Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymp… |
Alemtuzumab | SEP | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Northwestern University | United States, Sweden · Karolinska University Hospita… | 2011-06 → 2027-05 | Ouvrir |
| NCT07779460 A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevu… |
A Study Comparing Effectiveness o… | SEP | À vérifier | RECRUITING | En attente / non publié | Novartis Pharmaceuticals | United States · Novartis, East Hanover, United States | 2026-04-08 → 2026-12-31 | Ouvrir |
| NCT07609719 OSSIA — A Study of Ocrelizumab Administered Subcutaneously in Participa… |
OCR SC | SEP | Phase 4 | RECRUITING | En attente / non publié | Genentech, Inc. | United States, Puerto Rico · Atlanta Neuroscience Ins… | 2026-09-02 → 2029-02-28 | Ouvrir |
| NCT06711354 B-cell Depletion in Offspring to Women With MS Under Immunomodulatory T… |
Anti-CD20 Monoclonal Antibody | SEP | À vérifier | UNKNOWN | En attente / non publié | Region Stockholm | Non communiqué | 2025-06 → 2025-12 | Ouvrir |
| NCT06159712 CoSHEDRMS — Comparative Study of High-Efficacy Disease Modifying Treatm… |
CoSHEDRMS — Comparative Study of … | SEP | Non applicable | UNKNOWN | En attente / non publié | University of Aarhus | Denmark · Aarhus University, Aarhus, Denmark | 2023-11-27 → 2025-11 | Ouvrir |
| NCT05171972 Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment |
Ofatumumab | SEP | À vérifier | COMPLETED | En attente / non publié | Northwestern University | United States · University of Southern California, Lo… | 2022-01-29 → 2025-07-31 | Ouvrir |
| NCT06586177 REBELLION-MS — Understanding the 'Durable Effect' Concept of B-cell Mod… |
Anti-CD20 antibody | SEP | À vérifier | RECRUITING | En attente / non publié | Heinrich-Heine University, Duesse… | Germany · Heinrich-Heine University, Duesseldorf, Düs… | 2021-10-27 → 2028-12-31 | Ouvrir |
| NCT05266469 Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in … |
Exploring the Profiles of RMS Pat… | SEP | À vérifier | COMPLETED | En attente / non publié | Novartis Pharmaceuticals | United Arab Emirates · Novartis Investigative Site, A… | 2022-07-26 → 2024-11-11 | Ouvrir |
| NCT06869785 FILIOS — Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of… |
Ofatumumab approved dose | SEP | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | Novartis Pharmaceuticals | United States, Puerto Rico · Advent Neurology Clinic,… | 2025-03-13 → 2030-03-23 | Ouvrir |
| NCT06444113 KATHAROS — Concentration of Ofatumumab in the Breast Milk of Lactating … |
Ofatunumab | SEP | Phase 4 | ACTIVE_NOT_RECRUITING | En attente / non publié | Novartis Pharmaceuticals | United States, Germany, Italy, Poland, United Kingdom… | 2024-11-25 → 2026-10-29 | Ouvrir |
| NCT05090033 EAFToS — Characterizing the Use of Ofatumumab in a Real World Setting |
EAFToS — Characterizing the Use o… | SEP | À vérifier | COMPLETED | En attente / non publié | Novartis Pharmaceuticals | Australia · Novartis Investigative Site, Clayton, Aus… | 2022-12-08 → 2026-02-06 | Ouvrir |
| NCT05762003 CPE — Czech Pharmaco-epidemiological Study on Disease Modifying Drugs |
interferons, glatiramer acetate, … | SEP | À vérifier | COMPLETED | En attente / non publié | IMPULS Endowment Fund | Czechia · IMPULS Endowment Fund, Prague, Czechia | 2019-01-01 → 2021-12-31 | Ouvrir |
| NCT04676555 TIMIOS — Time and Motion Study for Ocrelizumab and Ofatumumab Administr… |
Ocrelizumab | SEP | À vérifier | COMPLETED | En attente / non publié | Hoffmann-La Roche | United States, Australia · Novartis Investigative Sit… | 2021-05-11 → 2021-10-21 | Ouvrir |
| NCT05528666 Risk Perception in Multiple Sclerosis |
Risk Perception in Multiple Scler… | SEP | À vérifier | COMPLETED | En attente / non publié | Novartis Pharmaceuticals | United States · Novartis Investigative Site, East Han… | 2021-09-09 → 2021-09-17 | Ouvrir |